key: cord-0781649-98xjbj6k
authors: Scheiblauer, Heinrich; Nübling, Claudius Micha; Wolf, Timo; Khodamoradi, Yascha; Bellinghausen, Carla; Sonntagbauer, Michael; Esser-Nobis, Katharina; Filomena, Angela; Mahler, Vera; Maier, Thorsten Jürgen; Stephan, Christoph
title: Antibody response to SARS-CoV-2 for more than one year − kinetics and persistence of detection are predominantly determined by avidity progression and test design
date: 2021-12-04
journal: J Clin Virol
DOI: 10.1016/j.jcv.2021.105052
sha: f051f9b1fd7af10e96254da2ac349972fd2eebed
doc_id: 781649
cord_uid: 98xjbj6k

BACKGROUND: Antibody detection of SARS-CoV-2 requires an understanding of its variation, course, and duration. METHODS: Antibody response to SARS-CoV-2 was evaluated over 5-430 days on 828 samples across COVID-19 severity levels, for total antibody (TAb), IgG, IgA, IgM, neutralizing antibody (NAb), antibody avidity, and for receptor-binding-domain (RBD), spike (S), or nucleoprotein (N). Specificity was determined on 676 pre-pandemic samples. RESULTS: Sensitivity at 30-60 days post symptom onset (pso) for TAb-S/RBD, TAb-N, IgG-S, IgG-N, IgA-S, IgM-RBD, and NAb was 96.6%, 99.5%, 89.7%, 94.3%, 80.9%, 76.9% and 92.8%, respectively. Follow-up 430 days pso revealed: TAb-S/RBD increased slightly (100.0%); TAb-N decreased slightly (97.1%); IgG-S and IgA-S decreased moderately (81.4%, 65.7%); NAb remained positive (94.3%), slightly decreasing in activity after 300 days; there was correlation with IgG-S (Rs=0.88) and IgA-S (Rs=0.71); IgG-N decreased significantly from day 120 (15.7%); IgM-RBD dropped after 30-60 days (22.9%). High antibody avidity developed against S/RBD steadily with time in 94.3% of patients after 430 days. This correlated with persistent antibody detection depending on antibody-binding efficiency of the test design. Severe COVID-19 correlated with earlier and higher antibody response, mild COVID-19 was heterogeneous with a wide range of antibody reactivities. Specificity of the tests was ≥99%, except for IgA (96%). CONCLUSION: Sensitivity of anti-SARS-CoV-2 assays was determined by test design, target antigen, antibody avidity, and COVID-19 severity. Sustained antibody detection was mainly determined by avidity progression for RBD and S. Testing by TAb and for S/RBD provided the highest sensitivity and longest detection duration of 14 months so far.

SARS-CoV-2 infection was declared a pandemic by WHO on March 11th, 2020 [1] . SARS-CoV-2 is a novel human coronavirus that can cause severe respiratory illness. Primary diagnosis is performed in the first 1-2 weeks after the onset of symptoms by direct detection of SARS-CoV-2 by nucleic acid amplification test (NAT) or antigen testing from respiratory secretions of nasal or throat swabs [2, 3] . Specific antibodies to SARS-CoV-2 develop relatively rapidly, with most patients becoming seropositive within 15-21 days [2] of infection, while viral load decreases and patients eventually become virus-negative. Antibody testing can therefore aid diagnosis in the acute phase adjunct to PCR or antigen testing [4] , and identify previous SARS-CoV-2 infection. Antibody detection may thus be useful to assess antibody response after infection or vaccination, for serosurveillance studies, and to distinguish vaccine-induced seropositivity from natural infection [4, 5] . However, interpretation of SARS-CoV-2 antibody responses remains challenging because of considerable heterogeneity among individuals [6] , and because the results of SARS-CoV-2 antibody assays may vary widely [7] . In addition, it is still unclear how binding antibodies relate to neutralizing antibodies [6, 8, 9] . Besides, there remains the crucial question how long an antibody response persists.

The aim of this study was to characterize the course and duration of antibody responses over more than one year in symptomatic patients covering the range of different COVID-19 symptom severity levels and by using 12 anti-SARS-CoV-2 tests encompassing various test designs, detected antibody types, target antigens, and by evaluating test sensitivity, antibody titers, neutralizing activity and antibody avidity.

Twelve anti-SARS-CoV-2 tests were used as described in Table 1 (sandwich, indirect, competitive), result interpretation (qualitative, quantitative), detection of neutralizing antibodies and determination of antibody avidity.

Samples were collected post symptom onset (pso) for a period of up to 430 days. All individuals tested positive for SARS-CoV-2-NAT and were symptomatic for COVID-19. Patients reported being unvaccinated or samples were collected prior to vaccine availability (12/21/2020 Testing was carried out according to manufacturers' instructions at the IVD Testing Laboratory at the Paul-Ehrlich-Institute. Sensitivity of anti-SARS-CoV-2 detection was calculated by standard formula, relative to the reported positive first diagnosis of SARS-CoV-2 infection by NAT. Antibody quantification was performed with the Liaison SARS-CoV-2 S1/S2 IgG test (Diasorin SpA, 13040 Saluggia, Italy), calibrated in arbitrary units (AU/mL) and a measuring JCV-D-21-00631 9 / 31 range of 15-400 AU/ml. The surrogate virus neutralization test (sVNT), (Genscript USA Inc., NJ 08854) detecting ACE-2 blocking Ab was used to refer to neutralizing antibodies (NAb) based on its correlation to virus neutralization test [11] . An inhibition rate of ≥20% was the cutoff for positive neutralization. All samples were subjected to avidity testing by recomLine SARS-CoV-2 avidity reagent (Mikrogen GmbH, 82061 Neuried, Germany) and quantified using BLOTrix Reader BTR48 and recomScan 3.4 test strip analysis software (Mikrogen GmbH). High avidity was defined as antibody binding capacity of ≥60%. Correlation between antibody quantification, avidity, neutralization and COVID-19 symptom severity were calculated using Spearman rank analysis [12] . Relative antibody binding efficiency (affinity) between different tests was determined by endpoint titration: samples were serially diluted (4-fold) up to the intercept with the assay's cutoff. The titer was calculated by linear interpolation, with a higher titer representing a higher relative affinity of the respective test. Specificity of the tests was determined by standard formula and 95% confidence intervals (Clopper-Pearson for binomial distributed data), 

The majority of subjects (84.2%) had mild ambulatory-treated COVID-19 symptoms (scores 1-2), 5.3% moderate hospitalized without respiratory therapy (score 3), 7.0% moderate hospitalized and respiratory therapy (score 4), the remaining 3.5% had severe COVID-19 (score >5) requiring ventilation and intensive treatment. Symptom severity correlated with antibody reactivity (Figure 1) . Severe COVID-19 symptom levels (>3) showed higher reactivity in all antibody tests compared to mild COVID-19 symptoms (p<0.001). However, within mild JCV-D-21-00631 10 / 31 COVID-19 (scores 1-3), there were large differences in antibody reactivity among individual patients and lower significance with COVID-19 severity (p 0.02 to 0.08). Therefore, COVID-19 severity was grouped into scores 1-3 for mild COVID-19 and scores 4-8 for severe COVID-19, and compared as shown in Table 1 and Figure 2 . Table 1 summarizes the sensitivity for the different tests over time, grouped into mild and severe COVID-19. (iv) NAb showed consistently high sensitivity of 91.6% from 60 days pso to 93.5% at 430 days pso, with NAb activity decreasing after 300 days pso, comparable to IgG-S and IgA-S. There was strong correlation between NAb and quantitative IgG-S (Rs=0.88) and with IgA-S (Rs=0.71) (Figure 3) . (v) IgG-N showed high initial sensitivity of 93.4% (mean of two IgG-N tests) up to 120 days pso and then dropped rapidly to 14.5 % by 430 days pso. (vi) TAb-N sensitivity was 99-100% until day 120 pso and decreased only slightly to 96.8% by day 430 pso.

TAb-N titers also decreased after 120 days of pso slowly and steadily, with a similar trend as [13, 14] . COVID-19 severity is known to correlate with antibody levels and persistence [15] [16] [17] [18] . In this study, the impact of COVID-19 symptom severity was differentiated between two groups, which were not limited to outpatient/hospitalized treatment but also by need for respiratory therapy, i.e. scores 1-3 versus scores 4-7 (requiring oxygen therapy or ventilation) [19, 20] . The picture within the mild COVID-19 group was heterogeneous with a wide range of antibody reactivities partly in overlap with severe COVID-19, as previously reported [18, 21] , and a corresponding variability between the different tests. Nevertheless, the results demonstrate a distinct test-specific pattern over time, allowing differences between tests to be classified. In summary, sensitivity and duration of antibody detection was dependent on test design and progression to high avidity. The sandwich design of TAb assays, and RBD/S-based assays, resulted in higher sensitivity over time based on increasing avidity for S/RBD. N-based assays were less sensitive than the corresponding S-based assays consistent with decreasing avidity for N. (i) TAb-S/RBD tests thus showed the highest and longest-lasting sensitivity, with stable antibody titers throughout the 14-month observation period and no predictable detection endpoint. (ii) The sensitivities of IgG-S/RBD and IgA-S were stable until 300 days pso followed by moderate decrease of antibody titers and in sensitivity of about 10-16% until 430 days pso. (iii) N-based assays showed an early decline in antibody titers starting from day 120 pso. Although sensitivity (test-positivity) of TAb-N decreased only slightly by day 430 pso, due to its sandwich design, declining antibody titers suggest a further decrease in sensitivity. For IgG-N, the decline was much faster after 120 days pso with short-JCV-D-21-00631 13 / 31 lived sensitivity becoming insignificant after 240-300 days pso. (iv) IgM-RBD sensitivity was essentially confined to the early phase (30-60 days pso), then declined rapidly, although not consistently, since some individuals showed persistent IgM. Therefore, IgM does not appear to be suitable for accurate timing of infection. (v) NAb, targeting RBD, showed consistently high or slightly increased base sensitivity (>20% inhibition) of 90-94% during 430 days pso, indicating more sustained duration of neutralization than published [18, 21] . Neutralization potency correlated strongly over time with quantitative IgG-S titers (Rs 0.88) [6, 18, 23] and with IgA-S (Rs 0.71) involved in mucosal immunity [22] . (vi) Antibody avidity developed mainly for RBD and S and increased slowly over time, from about 120 days pso to high avidity (>60%), remaining stable or increasing further up to 430 days pso. Most patients attained high avidity of 76% at one year and 94% after 430 days pso. Considering the time lag of avidity maturation, there was positive correlation with IgG-S antibody titers and neutralizing activity (Rs 0.55, 0.56).

In contrast to the immunogenic RBD and S, [24] , avidity against N was low, with 20-26% of patients showing high avidity.

Increasing avidity reflects affinity maturation of antibodies, mediation of cross-reactivity, and formation of long-lived plasma cells that can secrete antibodies in absence of antigen [9, [24] [25] [26] [27] [28] [29] .

Mature antibodies formed after acute infection may have up to 100-fold higher affinity [30, 31] .

On the other hand, the test design determines the extent to which a test benefits from higher affinity. This was confirmed by evaluation of the endpoint titers, reflecting the relative affinity and concentration of antibody in the sample. The sandwich test design of TAb-RBD assays exploited high avidity most effectively with 5-fold higher titers at high versus low avidity, and 9to 93-fold or 31-to 158-fold higher titers than the corresponding IgG-S or IgA-S test in the indirect assay format. In contrast, N-based TAb and IgG endpoint titers decreased 5-to 6-fold over time relative to S-based assays, in line with decreasing avidity to N. Nevertheless, TAb-N due to its sandwich design [32] , provided 5-120-fold higher baseline titers than indirect IgG-N (as the ratio TAb-S/RBD to IgG-S), explaining its high test-positivity in clinical samples and JCV-D-21-00631 14 / 31 making Tab-N suitable for long-term detection of anti-N. The sVNT assay for NAb, detecting TAb using a competitive test design, showed a base sensitivity between TAb sandwich and indirect IgG-S and IgA-S assays, with a time course similar to the latter.

Sensitivity of anti-SARS-CoV-2 tests in this study compared with high specificity of 99% or greater (except IgA) in 676 pre-pandemic blood donation samples, indicating reliable positive predictive value.

A limitation of the study is that no asymptomatic individuals were included. Nevertheless, the results of this study with the mildly symptomatic patients suggest a basically similar picture in asymptomatic individuals.

In conclusion, antibody detection showed a distinct pattern dependent on the antibody type detected, the target antigen, antibody avidity level, the test design, and severity of COVID-19.

Duration of detection was mainly driven by avidity progression for S/RBD and its exploitation by the respective test design. TAb assays based on S/RBD showed high sensitivity and persistent antibody detection for more than 14 months with consistent antibody titers and no predictable end of detection so far. 2) Quotient endpoint titers of Tab-RBD, IgG-S or Tab-N with the respective test below.

WHO Declares COVID-19 a Pandemic

Virological assessment of hospitalized patients with COVID-2019

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China

AACC Practical Recommendations for Implementing and Interpreting SARS-CoV-2 Emergency Use Authorization and Laboratory-Developed Test Serologic Testing in Clinical Laboratories

Antibody tests for identification of current and past infection with SARS-CoV-2

Antibody response to SARS-CoV-2 infection in humans: A systematic review

Evaluation of SARS-CoV-2 serology assays reveals a range of test performance

A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity

The variability of the serological response to SARS-corona virus-2: Potential resolution of ambiguity through determination of avidity (functional affinity)

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction

Spearman Rank Correlation (v1.0.3) in Free Statistics Software (v1.2.1). Office for Research Development and Education

Disease severity of the first COVID-19 wave in Germany using reporting data from the national notification system

The Proportion of SARS-CoV-2 Infections That Are Asymptomatic : A Systematic Review

Analysis of Humoral Immune Responses in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Differences in Antibody Kinetics and Functionality Between Severe and Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infections

Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19

SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay

Clinical Symptom Differences Between Mild and Severe COVID-19 Patients in China: A Meta-Analysis

Characteristics of and Important Lessons From the Coronavirus

COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study

IgA dominates the early neutralizing antibody response to SARS-CoV-2

Closing the serological gap in the diagnostic testing for COVID-19: The value of anti-SARS-CoV-2 IgA antibodies

COVID-19 and the Path to Immunity

SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans

Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells

Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity

Durability of Immunity to SARS-CoV-2 and Other Respiratory Viruses

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Kinetic and affinity limits on antibodies produced during immune responses

Maturation of an Antibody Response Is

Governed by Modulations in Flexibility of the Antigen-Combining Site

Enzyme immunoassay techniques an overview

We sincerely thank Prof. Franklin Kiesewetter and Dr. Maria Vogelsang for providing the samples from Erlangen and Nürnberg. We are also very grateful to Dr. Jork for providing the blood donation retention samples. We would like to thank the staff of the IVD Testing Laboratory at the Paul-Ehrlich-Institute for excellent technical assistance.